Insider Selling: Intuitive Surgical (NASDAQ:ISRG) EVP Sells $16,616.58 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Mark Brosius sold 46 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $361.23, for a total value of $16,616.58. Following the completion of the transaction, the executive vice president directly owned 835 shares of the company’s stock, valued at $301,627.05. The trade was a 5.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Brosius also recently made the following trade(s):

• On Wednesday, September 9th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The stock was sold at an average price of $350.20, for a total value of $8,054.60.
• On Friday, August 21st, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89.
• On Wednesday, August 19th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The shares were sold at an average price of $394.26, for a total transaction of $30,358.02.
• On Monday, August 17th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The shares were sold at an average price of $390.67, for a total transaction of $30,081.59.
• On Friday, July 31st, Mark Brosius sold 28 shares of Intuitive Surgical stock. The stock was sold at an average price of $351.00, for a total transaction of $9,828.00.
• On Wednesday, July 29th, Mark Brosius sold 28 shares of Intuitive Surgical stock. The shares were sold at an average price of $360.21, for a total transaction of $10,085.88.
• On Monday, July 27th, Mark Brosius sold 28 shares of Intuitive Surgical stock. The shares were sold at an average price of $344.00, for a total transaction of $9,632.00.
• On Friday, June 12th, Mark Brosius sold 25 shares of Intuitive Surgical stock. The stock was sold at an average price of $414.13, for a total transaction of $10,353.25.

Intuitive Surgical Stock Up 0.9%

Shares of ISRG stock traded up $3.08 during mid-day trading on Wednesday, hitting $353.24. 2,393,647 shares of the stock were exchanged, compared to its average volume of 2,438,106. The firm has a fifty day moving average of $379.70 and a 200 day moving average of $426.25. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88. The company has a market cap of $124.79 billion, a PE ratio of 40.46, a price-to-earnings-growth ratio of 2.77 and a beta of 1.47.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.83 billion. During the same quarter in the previous year, the business earned $1.81 EPS. Intuitive Surgical’s revenue for the quarter was up 18.4% compared to the same quarter last year. Equities analysts predict that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: A large meta-analysis found that da Vinci robotic-assisted surgery was associated with statistically significant improvements across 13 common benign conditions, including shorter hospital stays and faster returns to work versus laparoscopic and open surgery. The findings could support continued hospital adoption of Intuitive’s systems. New meta-analysis on da Vinci surgery outcomes
• Positive Sentiment: Analysts continue to view ISRG favorably. BTIG reaffirmed its Buy rating with a $469 price target, while other recent targets listed by Quiver Quantitative are materially above the current trading range. BTIG reaffirms Buy rating
• Positive Sentiment: Commentary at the Wells Fargo Healthcare Conference and related analyst coverage highlighted Intuitive’s long-term growth opportunity, innovation pipeline and expanding installed base. Articles also describe ISRG as trading at its cheapest valuation in roughly a decade, which may attract value-oriented investors despite near-term risks. Analyst views on Intuitive Surgical
• Neutral Sentiment: Investor discussions remain focused on the company’s strong margins, revenue growth and resilience, but also question whether the earnings multiple is justified while procedure trends moderate. ISRG earnings and procedure slowdown discussion
• Negative Sentiment: Recent coverage points to decelerating U.S. procedure growth, competitive pressure and possible effects from GLP-1 drugs. Rising costs and uncertainty around future growth have contributed to the stock’s recent weakness. Why ISRG underperformed the broader market
• Negative Sentiment: Reported insider activity shows numerous sales and no insider purchases over the past six months, a signal that may weigh on sentiment even though such transactions do not necessarily reflect management’s business outlook.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several recent analyst reports. BNP Paribas Exane raised shares of Intuitive Surgical to an “outperform” rating in a report on Tuesday, July 28th. Wells Fargo & Company reissued an “overweight” rating and set a $487.00 target price (down from $654.00) on shares of Intuitive Surgical in a research note on Friday, July 17th. Royal Bank Of Canada reduced their price target on shares of Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Intuitive Surgical in a research note on Friday, August 14th. Finally, Evercore set a $430.00 price objective on Intuitive Surgical in a report on Monday, July 6th. Twenty-two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $508.68.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rench Wealth Management Inc. boosted its position in shares of Intuitive Surgical by 2.0% during the 2nd quarter. Rench Wealth Management Inc. now owns 15,743 shares of the medical equipment provider’s stock valued at $6,261,000 after acquiring an additional 311 shares during the last quarter. IPG Investment Advisors LLC acquired a new stake in Intuitive Surgical during the second quarter worth about $218,000. National Pension Service increased its position in Intuitive Surgical by 3.1% during the second quarter. National Pension Service now owns 749,814 shares of the medical equipment provider’s stock worth $298,186,000 after purchasing an additional 22,372 shares during the last quarter. Engineers Gate Manager LP raised its stake in Intuitive Surgical by 509.1% during the second quarter. Engineers Gate Manager LP now owns 34,040 shares of the medical equipment provider’s stock worth $13,537,000 after purchasing an additional 28,451 shares during the period. Finally, Capital Analysts LLC raised its stake in Intuitive Surgical by 324.9% during the second quarter. Capital Analysts LLC now owns 2,354 shares of the medical equipment provider’s stock worth $936,000 after purchasing an additional 1,800 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc is a medical technology company that develops and manufactures robotic-assisted surgical systems and related products. Its technology is designed to support surgeons during minimally invasive procedures by providing enhanced visualization, instrument control and dexterity.

The company’s principal product is the da Vinci Surgical System, which is used across a range of specialties, including general surgery, urology, gynecology, cardiothoracic surgery and other procedures.